Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 14/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15975835 | 0.87 | MAP3K12 (0.45) | MAP3K12 | |
| SCHEMBL29435597 | 0.87 | MAP3K12 (0.45) | MAP3K12 | |
| SCHEMBL19754780 | 0.75 | MAP3K12 (0.40) | MAP3K12 | |
| SCHEMBL30867968 | 0.73 | NOS3 (0.34) | NOS3NOS1NOS2USP7 | |
| SCHEMBL83983 | 0.73 | NOS3 (0.34) | NOS3NOS1NOS2USP7 | |
| SCHEMBL15471948 | 0.72 | HTT (0.42) | NOS3NOS1NOS2USP7 | |
| SCHEMBL19754779 | 0.72 | MAP3K12 (0.44) | MAP3K12 | |
| SCHEMBL13278064 | 0.71 | MAP3K12 (0.40) | MAP3K12 | |
| SCHEMBL29910000 | 0.71 | GABRA1 (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL84407 | 0.71 | NOS3 (0.56) | NOS3NOS1NOS2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | MAP3K12 118/4885RXRA 3713/4885GRIN1 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.